The Medicines and Healthcare products Regulatory Agency (MHRA) has approved gepotidacin (Blujepa), a new kind of oral antibiotic pill to treat uncomplicated urinary tract infections (UTIs) in females aged 12 years and older, weighing at least 40 kg.

Uncomplicated UTIs are the most common bacterial infection in women, affecting around half of females in the UK. With drug-resistant bacteria increasing, new treatment options are critical in preventing treatment failure and complications, including sepsis or permanent kidney damage.

The active ingredient in the antibiotic targets and blocks two enzymes that bacteria need to replicate and multiply, making it effective against many drug resistant infections such as E. coli.

Julian Beach, MHRA Interim Executive Director, Healthcare Quality and

See Full Page